Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2009 by Queen Mary University of London.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Immunomedics, Inc.
Information provided by:
Queen Mary University of London
ClinicalTrials.gov Identifier:
NCT01279707
First received: April 12, 2010
Last updated: January 13, 2012
Last verified: May 2009
  Purpose

The treatment of adult B-cell acute lymphoblastic leukaemia (ALL) has progressed considerably in the past 3 decades, particularly due to intensification of chemotherapies, improved supportive care and the incorporation of stem cell transplantation. However, the maximum tolerability of standard chemotherapeutics has been reached in ALL. Using conventional chemotherapy, 80-85% of adults with ALL will achieve a complete remission (CR). Unfortunately treatment at relapse is generally unsuccessful and rarely results, in long-term survival (7% survival at 5 years). Therefore, the investigators are exploring novel treatment strategies through the use of monoclonal antibodies (MoAbs) directed at surface antigens on leukaemic blasts. Using MoAbs directed against surface proteins on B cells has had excellent results in other B-cell diseases such as low and high grade non-Hodgkin lymphomas, without additional toxicity. There has also been limited evidence from small studies and case reports of the efficacy of MoAbs in ALL.

This is a Phase I/II study to determine the safety and tolerability of the combination of veltuzumab and epratuzumab with intensive chemotherapy in patients with relapsed B-cell ALL. A maximum of 51 patients will be treated with a combination of UKALL XII induction chemotherapy and the monoclonal antibodies veltuzumab and epratuzumab. Veltuzumab and epratuzumab are humanised monoclonal antibodies that target CD20 and CD22 surface proteins, respectively. Both of these proteins are expressed on ALL tumour B cells.

One group of patients will receive modified UKALL XII chemotherapy + veltuzumab; a second, modified UKALL XII chemotherapy + epratuzumab and if limited toxicity is found in these first 2 groups, a third group will receive, modified UKALL XII chemotherapy + both veltuzumab and epratuzumab. Patients will be assessed for safety, tolerability and disease response. Safety and tolerability will be measured by the number of Dose Limiting Toxicities (DLTs) in each group. Disease response will be measured by the microscopic appearance of patient bone marrow samples at day 29, and by molecular tests for tumour cells in bone marrow.


Condition Intervention Phase
Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia
Biological: humanised monoclonal antibody, veltuzumab
Biological: humanised monoclonal antibody epratuzumab
Biological: humanised monoclonal antibodies veltuzumab and epratuzumab
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I/II Study Combining Humanised Anti-CD20 (Veltuzumab), Anti-CD22 (Epratuzumab) and Both Monoclonal Antibodies With Intensive Chemotherapy in Adults With Recurrent or Refractory B-precursor Acute Lymphoblastic Leukaemia (ALL)

Resource links provided by NLM:


Further study details as provided by Queen Mary University of London:

Primary Outcome Measures:
  • The total number of dose limiting toxicity events (DLTs) to measure safety and tolerability [ Time Frame: Day 29 ] [ Designated as safety issue: Yes ]
    The primary objective is to assess the safety and tolerability of the combination of veltuzumab and/or epratuzumab with intensive chemotherapy for recurrent or refractory adult B-precursor ALL.


Secondary Outcome Measures:
  • Morphological and molecular remission in bone marrow [ Time Frame: Day 29 ] [ Designated as safety issue: No ]

    Achievement of morphological complete remission on Day 29 bone marrow

    Efficacy of treatment to achieve MRD negativity, and investigate a possible association between the intensity of CD20 and CD22 antigen expression and treatment activity.



Estimated Enrollment: 55
Study Start Date: January 2010
Estimated Study Completion Date: April 2014
Estimated Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A: Veltuzumab and chemotherapy
Veltuzumab and modified UKALL XII chemotherapy
Biological: humanised monoclonal antibody, veltuzumab
Veltuzumab with modified UKALL XII induction chemotherapy. Veltuzumab will be administered at 200 mg/m2 IV on Day 8 and subsequently, (if tolerated on Day 8), over 1 hour on Days 15, 22, 29.
Experimental: B: epratuzumab and chemotherapy
epratuzumab and modified UKALL XII chemotherapy
Biological: humanised monoclonal antibody epratuzumab
Epratuzumab with modified UKALL XII induction chemotherapy. Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29.
Experimental: C: veltuzumab and epratuzumab and chemotherapy
Veltuzumab and Epratuzumab and modified UKALL XII chemotherapy
Biological: humanised monoclonal antibodies veltuzumab and epratuzumab
Epratuzumab + Veltuzumab with modified UKALL XII induction chemotherapy. Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29. Veltuzumab will be administered at 200 mg/m2 IV over 2 hours on Day 8 and over 1 hour on Days 15, 22 and 29. Veltuzumab will be infused 1 hour after the infusion of epratuzumab.

  Eligibility

Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Aged 16 years or over
  2. Confirmed diagnosis of recurrent or refractory B-precursor ALL [according to the WHO classification].
  3. Greater than 5% blasts in the bone marrow
  4. WHO/ECOG performance status of 0-2 and well enough to receive intensive combination chemotherapy.
  5. Negative pregnancy test in women of childbearing potential. Women will not be considered of child bearing potential if they have undergone surgical removal of the uterus or are post menopausal and have been amenorrhoeic for at least 24 months.
  6. Patients must have adequate organ function:

    • Renal function - serum creatinine <2.5 x ULN or eGFR>50ml/min (measured EDTA or estimated creatinine clearance e.g Cockcroft & Gault)
    • Liver function (bilirubin/ALT <2.5 x ULN)
  7. Patients must be able to comply with the study schedule.

Exclusion Criteria:

  1. Patients should not have received chemotherapy for current episode of relapsed ALL (except corticosteroids for a maximum of 10 days, before joining the study).
  2. Patients with co-morbidities: e.g. uncontrolled hypertension and or poorly controlled diabetes which in the PI's opinion makes them unsuitable for the study.
  3. Patients with severe psychiatric disorders which in the PI's opinion makes them unsuitable for trial participation.
  4. Females of childbearing potential and all males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) for the duration of the study and for up to 3 months after the last dose of study medication. Note: Subjects are not considered of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal.
  5. Females of childbearing potential must have a negative pregnancy test within 7 days prior to starting the study.
  6. Females must not be breastfeeding.
  7. Patients may not receive any other investigational agent during the study.
  8. Patients should not have received any antibody therapy within 3 months of joining this study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01279707

Contacts
Contact: Matthew Smith, Dr 0203 4656070

Locations
United Kingdom
University Hospitals Birmingham NHS Foundation Recruiting
Birmingham, United Kingdom, B15 2TH
Contact: Fiona Clark, Doctor       Fiona.Clark@uhb.nhs.uk   
Principal Investigator: Fiona Clark, Doctor         
University of Bristol Foundation Trust Recruiting
Bristol, United Kingdom, BS2 8BJ
Contact: David Marks, Professor       David.Marks@uhbristol.nhs.uk   
Principal Investigator: David Marks, Professor         
University Hospital of Wales Not yet recruiting
Cardiff, United Kingdom, CF14 4XN
Contact: Clare Rowntree, Doctor       clare.rowntree@cardiffandvale.wales.nhs.uk   
Principal Investigator: Clare Rowntree, Doctor         
Beatson West of Scotland Cancer Centre Not yet recruiting
Glasgow, United Kingdom, G12 0YN
Contact: Mhairi Copland, Doctor       M.Copland@clinmed.gla.ac.uk   
Leeds Teaching Hospitals NHS Trust Recruiting
Leeds, United Kingdom, LS9 7TF
Contact: Maria Gilleece, Doctor       M.H.Gilleece@leeds.ac.uk   
Barts and the London NHS Trust Recruiting
London, United Kingdom, EC1A 7BE
Contact: Matthew Smith, Doctor       matthew.smith2@bartsandthelondon.nhs.uk   
Principal Investigator: T. Andrew Lister, Professor         
Royal Free Hampstead NHS Trust Recruiting
London, United Kingdom, NW3 2QG
Contact: Adele Fielding, Doctor       a.fielding@medsch.ucl.ac.uk   
Newcastle University Recruiting
Newcastle, United Kingdom, NE2 4HH
Contact: Matthew Collin, Doctor       matthew.collin@ncl.ac.uk   
Principal Investigator: Matthew Collin, Doctor         
Nottingham City Hospital Not yet recruiting
Nottingham, United Kingdom, NG5 1PB
Contact: Andrew McMillan, Doctor       andrew.mcmillan@nuh.nhs.uk   
Principal Investigator: Andrew Mcmillan, Doctor         
Plymouth Hospitals NHS Trust Not yet recruiting
Plymouth, United Kingdom, PL6 8DH
Contact: Simon Rule, Doctor         
Sponsors and Collaborators
Queen Mary University of London
Immunomedics, Inc.
Investigators
Principal Investigator: Matthew Smith, Doctor Barts and The London NHS Trust
  More Information

No publications provided

Responsible Party: Mr Gerry Leonard, Queen Mary University of London
ClinicalTrials.gov Identifier: NCT01279707     History of Changes
Other Study ID Numbers: 6125
Study First Received: April 12, 2010
Last Updated: January 13, 2012
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Epstein-Barr Virus Infections
Burkitt Lymphoma
Leukemia
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Tumor Virus Infections
Lymphoma, Non-Hodgkin
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoma, B-Cell
Neoplasms, Experimental
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antibodies
Immunoglobulins
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 22, 2014